Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.30 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.30 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2150743 | 1.00 | HTR2A (0.33) | HTR2ASLC6A4KCNH2PSEN1PSEN2 | |
| SCHEMBL30582950 | 0.86 | PSEN1 (0.40) | HTR2ASLC6A4KCNH2PSEN1PSEN2 | |
| SCHEMBL20237851 | 0.86 | PSEN1 (0.40) | HTR2ASLC6A4KCNH2PSEN1PSEN2 | |
| SCHEMBL29668771 | 0.86 | PSEN1 (0.40) | HTR2ASLC6A4KCNH2PSEN1PSEN2 | |
| SCHEMBL23148369 | 0.86 | PSEN1 (0.40) | HTR2ASLC6A4KCNH2PSEN1PSEN2 | |
| SCHEMBL23148371 | 0.86 | PSEN1 (0.40) | HTR2ASLC6A4KCNH2PSEN1PSEN2 | |
| SCHEMBL20237852 | 0.86 | PSEN1 (0.40) | HTR2ASLC6A4KCNH2PSEN1PSEN2 | |
| SCHEMBL20237848 | 0.86 | PSEN1 (0.40) | HTR2ASLC6A4KCNH2PSEN1PSEN2 | |
| SCHEMBL21063771 | 0.86 | PSEN1 (0.40) | HTR2ASLC6A4KCNH2PSEN1PSEN2 | |
| SCHEMBL7005259 | 0.85 | HTR1B (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133140-B2 | Cycloalkylamne derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-09-15 | — | — | US | disclosed |
| US-20120295943-A9 | CYCLOALKYLAMINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-11-22 | — | — | US | disclosed |
| US-20120122941-A1 | CYCLOALKYLAMINE DERIVATIVES | MARUMOTO SHINJI (JP) | 2012-05-17 | — | — | US | disclosed |
| WO-2010021351-A1 | CYCLOALKYLAMINE DERIVATIVE | 第一三共株式会社 (JP) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295943-A9 | CYCLOALKYLAMINE DERIVATIVES | CASR, CALCR, CALCRL | HTR2A 616/4885SLC6A4 2396/4885KCNH2 633/4885 |
| US-20120122941-A1 | CYCLOALKYLAMINE DERIVATIVES | CASR, CALCR, CALCRL | HTR2A 616/4885SLC6A4 2396/4885KCNH2 633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.